Clinical trial · Observational
Asprosin in Breast Cancer
Diagnostic Value of Asprosin As a Biomarker in Breast Cancer
NCT06592560CI-TRIAL-00080664not yet recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To evaluate the clinical utility of Asprosin measurement in breast cancer patients in comparison with healthy controls and patients with benign breast lesions. To compare between Asprosin and the routine markers (CEA, CA15-3) as biomarkers for breast cancer diagnosis
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| ELISA | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- label
- Healthy people
- interventionNames
- Device: ELISA
- label
- Patients with benign breast lesions
- interventionNames
- Device: ELISA
- label
- Patients with breast cancer
- interventionNames
- Device: ELISA
Primary outcomes (1)
- measure
- Diagnostic value of Asprosin as a biomarker in breast cancer
- timeFrame
- Baseline
- description
- Evaluation of the clinical utility of measurement of asprosin as a non invasive biomarker in the diagnosis of breast cancer
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 60 Years
Show eligibility criteria text
Inclusion Criteria: \- Females aged (40 ± 20 years) who did not receive any chemotherapy or surgical treatment and they will be divided as follow: Group 1: healthy controls from healthy volunteers. Group 2: patients with benign breast lesions. Group 3: breast cancer patients. Exclusion Criteria: * 1- Female patients with any other type of malignant or benign tumors. 2- Past history of chemotherapy or surgical treatment of cancer.
References
Publications (0)
Data not yet available
No reference posted for this study.